Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat versus Cerezyme in Gaucher disease type 3 patients stabilized on enzyme replacement therapy
2021-005402-10Phase 3Active
- Sponsor
- Sanofi
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of venglustat in Gaucher disease type 3 (2 arms), sponsored by Sanofi. Primary endpoint: Change in Scale for Assessment and Rating of Ataxia modified total score. Started Jan 2022; status: active.
02
Drugs
venglustat
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on 2021-005402-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005402-10.